AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19 (Trial H4: AZD7442)
Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
A PHASE3 clinical study on COVID-19, this trial is completed. The trial is conducted by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections and has accumulated 8 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Mar 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Mar 2025 [monthly]
Completed PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 3 earlier versions
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Jun 2023 — Jun 2024 [monthly]
Active Not Recruiting PHASE3
-
Apr 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE3
First recorded
Feb 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- AstraZeneca
- Cardiothoracic Surgical Trials Network
- International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
- Kirby Institute
- Medical Research Council
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- Prevention and Early Treatment of Acute Lung Injury
- US Department of Veterans Affairs
- University of Copenhagen
- University of Minnesota
- Washington D.C. Veterans Affairs Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .